European Stocks Gain as Oil Eases; Biotech Abivax Plunges 40% on Trial Safety Fears

Market Overview

European equity markets closed higher today, supported by a constructive macro backdrop as global oil prices pared recent gains. The pan-European Stoxx 600 index rose 0.44%, with Germany’s DAX and France’s CAC 40 following suit with modest gains.

The primary catalyst for the broader market lift was a pullback in crude energy costs. Front-month Brent crude futures fell roughly 1.2%, easing headline inflation anxieties that have kept central bank interest-rate decisions under a microscope. The relief in energy prices particularly boosted airline and travel stocks, while defense and banking sectors also notched steady gains.

Individual Stock Focus: Abivax Collapse

While macro sentiment remained resilient, the biotech sector experienced sharp idiosyncratic volatility. Shares of French drugmaker Abivax SA (ABVX) collapsed by more than 40% in high-volume trading, erasing billions in market value.

The dramatic sell-off came immediately after the company released long-awaited Phase 3 ABTECT clinical maintenance data for its lead drug candidate, obefazimod, an oral therapy targeting ulcerative colitis.

While the trial demonstrated “best-in-disease” efficacy figures—delivering a placebo-adjusted clinical remission rate of approximately 40%—the stellar results were entirely overshadowed by a critical safety overhang:

• Safety Signal: Investors panicked after data revealed that a few patients treated with the higher dose of obefazimod developed rare malignancy (cancer) cases.

• Company Response: Abivax management stated the cases were deemed unrelated to the treatment and were not clustered around a specific organ, confirming they still plan to file for FDA approval late this year.

• Wall Street Reaction: The reassurance failed to calm the market. Jefferies swiftly downgraded the stock from Buy to Hold, slashing its price target by nearly 44% and citing the sudden safety profile concerns as a severe, long-term drag on the asset’s commercialization and previous status as a prime Big Pharma takeover target.

Key Takeaway: Today’s session perfectly highlights the division between macro-driven market resilience and the extreme binary risks inherent to biotech investing. While a cool-down in energy costs floated the broader indexes, bad news on safety can decouple a single stock instantly.